Rhythm Achieves Breakthrough in Rare Obesity – Study Success Fuels Stock Expectations

• Success with IMCIVREE®:  Rhythm achieves breakthrough in previously untreatable form of obesity – application for approval planned for 2025. • Market potential & expansion: Revenue opportunity of $984 million by 2030 – China strategy realigned after license buyback. Rhythm Pharmaceuticals (NASDAQ: RYTM) positions itself as a pioneer in rare forms of obesity with IMCIVREE®. Two recent developments bring new hope to patients – and lucrative market opportunities to Rhythm. Success in the TRANSCEND trial The Phase 3 study...